This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Acasti Pharma Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Wichtige Informationen
-28.1%
Wachstumsrate der Gewinne
-30.2%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 74.9% |
| Wachstumsrate der Einnahmen | 26.1% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 16 Feb 2023 |
Jüngste Aktualisierungen zum künftigen Wachstum
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2025 | 97 | -38 | 27 | N/A | 3 |
| 3/31/2024 | 160 | 161 | 12 | -25 | 2 |
| 3/31/2023 | N/A | -6 | -17 | -17 | 2 |
| 12/31/2022 | N/A | -17 | -16 | -16 | N/A |
| 9/30/2022 | N/A | -17 | -17 | -17 | N/A |
| 6/30/2022 | N/A | -11 | -19 | -19 | N/A |
| 3/31/2022 | N/A | -10 | -17 | -17 | N/A |
| 12/31/2021 | 0 | -12 | -16 | -16 | N/A |
| 9/30/2021 | 0 | -11 | -15 | -15 | N/A |
| 6/30/2021 | 0 | -18 | -14 | -14 | N/A |
| 3/31/2021 | 0 | -20 | -14 | -14 | N/A |
| 12/31/2020 | 0 | 3 | -16 | -15 | N/A |
| 9/30/2020 | N/A | -6 | -19 | -18 | N/A |
| 6/30/2020 | N/A | -21 | -21 | -20 | N/A |
| 3/31/2020 | N/A | -26 | -23 | -23 | N/A |
| 12/31/2019 | N/A | -56 | -29 | -29 | N/A |
| 9/30/2019 | N/A | -46 | -29 | -29 | N/A |
| 6/30/2019 | N/A | -42 | -27 | -27 | N/A |
| 3/31/2019 | N/A | -39 | -25 | -25 | N/A |
| 12/31/2018 | N/A | -31 | -20 | -19 | N/A |
| 9/30/2018 | N/A | -34 | -17 | -16 | N/A |
| 6/30/2018 | N/A | -20 | -13 | -13 | N/A |
| 3/31/2018 | N/A | -17 | -10 | -10 | N/A |
| 3/31/2017 | N/A | -8 | -7 | -5 | N/A |
| 11/30/2016 | 0 | -7 | N/A | -5 | N/A |
| 8/31/2016 | 0 | -7 | N/A | -5 | N/A |
| 5/31/2016 | 0 | -6 | N/A | -6 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ACST's earnings are forecast to decline over the next 3 years (-28.1% per year).
Ertrag vs. Markt: ACST is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: ACST is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: ACST's revenue (26.1% per year) is forecast to grow faster than the Canadian market (5.5% per year).
Hohe Wachstumseinnahmen: ACST's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if ACST's Return on Equity is forecast to be high in 3 years time